1. Supplemental figure 1 ROS production in MM cell line (KMM1) treated with bortezomib and DCA. ROS production was marginally increased by DCA in combination with bortezomib. p<0.0001 p=0.0023

2. Cut off is median (= 194.1968) p=0.24 (log rank) (N=27) Cut off is median (= 4251.795) (N=27) p=0.84 (log rank) p=0.29 (log rank) Cut off is median (= 9.98) (N=27) p=0.20 (log rank) Cut off is median (= 287) (N=27) Supplemental figure 2 Overall survival analysis of our cohort which was sub-grouped by expression of glycolysis- related genes except LDH. None of these genes serves as prognostic factor in our cohort.

3. LDHA (NM_005566 ) p=0.031 (Log-rank) PDK1 (NM_002610 ) p=0.9315 (Log-rank) PDK1 ( AU146532 ) p=0.7987 (Log- rank) HIF1A (TT2, NM_001530 ) p=0.1154 (Log- rank) GLUT1 (TT2, AI091047 ) p=0.2379 (Log-rank) GLUT1 (TT2, NM_006516) p=0.8554 (Log- rank) MYC (TT2, NM_002467 ) p=0.2978 (Log- rank) MYC (TT2, BF514781 ) p=0.6918 (Log- rank) Supplemental figure 3 Overall survival analysis in TT2 cohort (Re-analyzed using data by Zani et al.). Cases were sub- grouped by expression of LDHA, cMYC, GLUT1, HIF1A and PDK1. LDHA was the only prognostic factor.

4. p=0.0016p<0.0001 p=0.9412p<0.0001 Kruskal-Wallis test And Dunns multiple Comparison test * Supplemental figure 4 Expression of LDHA, cMYC, GLUT1, HIF1A and PDK1 in the 8 molecular subgroups of MM utilizing database deposited by Zhan et al. All genes except GLUT1 showed significant heterogeneous expressions. *: LDHA expression of CD2 group was significantly lowest than the other groups.

5. p=0.2806 p=0.2774p=0.0805p=0.5309 p=0.1003 p=0.2610 p=0.9207p=0.3977 Supplemental figure 5 The association between the expression of LDHA, cMYC, GLUT1, HIF1A and PDK1 in 6 molecular subgroups of human myeloma cell lines utilizing data of Moreaux et al. There was no significant difference in expression of these genes within subgroups.